{
    "filename": "0001193125-25-220898_primary_doc.xml",
    "path": "d:\\Files\\Code\\Funkles-SEC\\FunklesScraper\\..\\filings_cache\\0001193125-25-220898_primary_doc.xml",
    "date": "2025-09-26",
    "form": "SCHEDULE 13D",
    "file_type": "SCHEDULE 13D",
    "original_filename": "primary_doc.xml",
    "accession": "0001193125-25-220898",
    "cik": "0001962738",
    "label": "Signal activist investment or strategic involvement",
    "summary": "Panacea Venture Healthcare Fund II, L.P., Panacea Venture Healthcare Fund II GP Company, Ltd., Panacea Innovation Limited, and James Huang jointly filed a Schedule 13D, reporting beneficial ownership in CASI Pharmaceuticals, Inc. As of September 26, 2025, James Huang beneficially owns 3,661,571 Ordinary Shares, representing 19.9% of the class, which includes shares held by Panacea Venture entities and personal options. On September 26, 2025, Panacea Venture Healthcare Fund II, L.P. purchased 1,500,000 Ordinary Shares from the Issuer, and James Huang is set to be appointed to the Issuer's Board of Directors effective October 1, 2025. The Reporting Persons acquired the securities for investment purposes and may explore various corporate actions.",
    "share %": 0.2363435117750877
}